GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

Chime Biologics, a leading global CDMO that enables its partners' success in biologics, and Waterstone, a reliable partner ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...

Entero has signed a binding term sheet in which private biotech Journey is slated to acquire 99% of Entero’s equity, ...

CEO Roberto Iacone admitted in an interview that the market remains tough, even for a biotech in the red-hot ADC world. But ...

Secures $3.2m in PIPE Financing -- $50m Term Sheet Obtained for Available Financing under Equity Line of Credit -BOSTON and LONDON, Nov. 14, ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

As pharmaceutical companies embrace antibody-drug conjugates (ADCs) as a way to treat cancer, drug services providers are ...

Based outside Boston, MilliporeSigma was formed after Merck KGaA acquired St. Louis-based Sigma-Aldrich Corp. for $17 billion ...

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

As per DelveInsight estimates, North America is anticipated to dominate the global antibody-drug conjugate market during the forecast period. In the cancer type segment of the antibody-drug ...